# A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

> **NCT03224598** · PHASE2 · COMPLETED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 39 (actual)

## Conditions studied

- Dermatosis Papulosa Nigra

## Interventions

- **DRUG:** A-101 Topical Solution 40%

## Key facts

- **NCT ID:** NCT03224598
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-26
- **Primary completion:** 2019-01-08
- **Final completion:** 2019-01-08
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03224598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03224598, "A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03224598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*